Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tshireletso: CAB-LA PrEP in Postpartum Breastfeeding Women in Botswana
NCT05986084Phase 4Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Persistence of CAB-LA injections at 24 months, Uptake of CAB-LA injections at 24 months and 4 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05986084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986084.